iCell Gene Therapeutics
CAR-T cell therapy (private)
Privately held: no public share price · United States
Assets
(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | BCMA / CD19Cell therapy | Inflammatory Bowel DiseaseSystemic Lupus Erythematosus Ulcerative Colitis, Crohn's Disease | |
Anti-CD33 CAR T-cellsNo recent activity | Phase 1 | CD33Cell therapy | Acute Myeloid Leukemia |
| Phase 1 | BCMA / CD19Cell therapy | Multiple MyelomaSystemic Lupus Erythematosus | |
| Phase 1 | CD33; CLL1 (CLEC12A)Cell therapy | Acute Myeloid Leukemia |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
No financial reports recorded.